Dotti Patch, Extended Release
Product Images NDC 72162-2032

Product Visual Gallery

This gallery contains 17 technical images submitted to the FDA as part of the official labeling for Dotti (NDC 72162-2032). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Dotti Estradiol Transdermal System 1)

Chemical structure of estradiol, the active ingredient in the DOTTI transdermal patch. The diagram depicts the molecular framework indicating hydroxy groups and hydrogen atoms attached to the steroid nucleus.*

FDA Label Image

4a (Dotti Estradiol Transdermal System 10)

An instructional illustration showing two hands removing a protective backing from a rectangular transdermal patch, likely demonstrating how to prepare the DOTTI estradiol extended-release patch for application.*

FDA Label Image

4b (Dotti Estradiol Transdermal System 11)

An instructional illustration showing two hands peeling apart the protective liner from a DOTTI estradiol transdermal patch, extended release, 0.025 mg/d. The image demonstrates the preparation step before applying the medication patch to the skin.*

FDA Label Image

4c (Dotti Estradiol Transdermal System 12)

An instructional illustration showing a hand applying a small, round transdermal patch to the lower abdominal area of a person's body. The image demonstrates the proper placement of the patch on the skin.*

FDA Label Image

4d (Dotti Estradiol Transdermal System 13)

An instructional diagram depicting hands applying a transdermal patch to the skin. The image shows the placement procedure for a patch, likely related to the DOTTI estradiol extended-release patch.*

FDA Label Image

4e (Dotti Estradiol Transdermal System 14)

An instructional illustration showing hands applying a transdermal patch to the skin, demonstrating the proper placement and pressing technique for secure adhesion.*

FDA Label Image

4f (Dotti Estradiol Transdermal System 15)

An instructional line drawing showing the placement of a transdermal patch on the upper arm or shoulder area of a person's body. The illustration emphasizes correct patch application on the skin.*

FDA Label Image

4g (Dotti Estradiol Transdermal System 16)

An illustration showing a hand applying a small round transdermal patch to the lower abdomen area of a person's skin. The image visually demonstrates the method of applying a DOTTI estradiol extended-release patch.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 2)

An illustration showing a cross-sectional view of the DOTTI estradiol transdermal patch, identifying three distinct layers: the backing, the adhesive containing estradiol, and the protective liner.*

FDA Label Image

Figure 1 (Dotti Estradiol Transdermal System 3)

A line graph showing concentration (pg/mL) versus time (days) for four different dosage levels of a drug: 0.1 mg/day, 0.075 mg/day, 0.05 mg/day, and 0.0375 mg/day. The graph tracks how concentration changes over a period of approximately 4 days for each dose.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 4)

A bar graph comparing mean (SD) reduction from baseline at Week 4, Week 8, and Week 12 for Estradiol 0.0375 mg/day versus placebo. Estradiol shows greater reduction than placebo at all time points, with values and sample sizes indicated for each group. A note at the bottom indicates statistical significance (p<0.05) between Estradiol and placebo.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 5)

A line graph showing percent change from baseline over treatment durations of 26, 52, 78, and 104 weeks. It compares multiple doses of estradiol (0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day) and a placebo. Each dose is represented by a different line style and marker in the legend below the graph.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 6)

A line graph showing percent change from baseline over treatment duration in weeks (26, 52, 78, 104). It compares Estradiol at 0.1 mg/day, 0.05 mg/day, 0.0375 mg/day, 0.025 mg/day and placebo, with annotations marking statistically significant differences (p<0.05) between groups.*

FDA Label Image

1 (Dotti Estradiol Transdermal System 7)

Text panel from DOTTI estradiol transdermal system outlining days for patch changes. It lists paired days of the week (Sun/Wed, Mon/Thu, Tue/Fri, Wed/Sat, Thu/Sun, Fri/Mon, Sat/Tue) with checkboxes for selecting the two days on which to change the patch.*

FDA Label Image

2 (Dotti Estradiol Transdermal System 8)

An illustration showing a hand applying a DOTTI 0.025 mg/d estradiol extended-release transdermal patch to the lower abdominal skin area. The image demonstrates the intended placement of the patch for transdermal delivery.*

FDA Label Image

3 (Dotti Estradiol Transdermal System 9)

The image shows a DOTTI transdermal patch for estradiol .025 mg/d, designed for extended release. The patch is white and rectangular with a slightly curved edge on one side. The labeler is Bryant Ranch Prepack. The product is a human prescription drug.*

FDA Label Image

Label (Lbl721622032)

DOTTI estradiol transdermal system, USP patch delivering 0.025 mg/day, labeled with NDC 72162-2032, provided in a pack of 8 systems. The label includes storage instructions, usage warnings, and manufacturer details showing Bryant Ranch Prepack and Amneal Pharmaceuticals, LLC.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.